+ Watch AMRN
on My Watchlist
The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
hyertiglyceridemic drug Vasepa approved by FDA needs NCE approval drug has no side affects cash and cash equivalents o $ 215.1M no cash outflow Questions about a take over
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions